CD19 and myeloid sarcoma: Analyzing the time period 12 months before the MS relapse in an event-driven manner, CD4+ T cells, CD8+ T cells, CD19+ B cells, as well as naïve and memory T cell subsets and Treg cells, immature B cells and B reg cells, were stable and did not significantly differentiate CR patients from PR patients (Figures 6A–D,F,I).